By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

CVS’s expansion into primary care is expected to drive long-term growth, while Gilead’s strong pipeline and market position in virology and oncology support its continued dividend growth.

Gilead Sciences plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with just a single shot every year, STAT tells us.

CVS Health Corp., one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from ...

CVS Health Corp(NYSE: CVS), Gilead Sciences, Inc.(NASDAQ: GILD), and Omega Healthcare Investors Inc(NYSE: OHI) are three awesome-sauce healthcare stocks that operate in different corners of the ...

CVS Health Corp(NYSE: CVS), Gilead Sciences, Inc.(NASDAQ: GILD), and Omega Healthcare Investors Inc(NYSE: OHI) are three awesome-sauce healthcare stocks that operate in different corners of the ...